Summit Therapeutics Inc. Increase Decrease Through Business Combinations Deferred Tax Liability Asset
Summit Therapeutics Inc. (SMMT) reported Increase Decrease Through Business Combinations Deferred Tax Liability Asset of GBP 0 for the 12-month period ending 2019-01-31, per its 20-F filed 2019-03-29.
Discontinued › Notes › Income Taxes
ifrs-full:IncreaseDecreaseThroughBusinessCombinationsDeferredTaxLiabilityAsset · last filed 2019-03-29
| Period end | Increase Decrease Through Business Combinations Deferred Tax Liability Asset 12 month |
|---|---|
| 2019-01-31 | 0.00 GBP 20-F · filed 2019-03-29 |
| 2018-01-31 | 1.81M GBP 20-F · filed 2019-03-29 |
| 2017-01-31 | 0.00 GBP 20-F · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |